News - SAb Biotherapeutics

November 30, 2020

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19

November 30, 2020 07:45 AM EASTERN STANDARD TIME SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a…

RSS

SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19

August 21, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19

August 11, 2020

SAB Biotherapeutics Awarded $35.6M From U.S. Department Of Defense For COVID-19 And Scaling Rapid Response Antibody Program

August 6, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

July 30, 2020

SAB Biotherapeutics Closes Series B Funding

July 17, 2020

Cows Help With COVID-19 Treatment, No Bull

June 17, 2020

Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

June 16, 2020

SAB Biotherapeutics President And CEO Eddie J. Sullivan, PhD, Featured On COVID-19 Panel At BIO Digital 2020

June 8, 2020

This Cow’s Antibodies Could Be The Newest Weapon Against COVID-19

June 5, 2020

SAB Biotherapeutics Confirms Neutralizing Antibodies To SARS-CoV-2 And Begins Clinical Manufacturing Of Novel COVID-19 Therapeutic Candidate

May 28, 2020

Researchers Use Cows To Develop Antibody Treatment

May 20, 2020